Study for adults with Ph-negative ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial looks at how to treat a type of leukemia called Ph-negative ALL in adults. It may help people by testing a treatment approach specifically for this leukemia subtype.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 60.
- You have newly diagnosed (de novo) Ph-negative ALL.
- Your day-to-day functioning score is ECOG 0 to 2, or higher only because of the leukemia.
- You can and agree to sign informed consent.
- You are not pregnant and you can safely participate per study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for adults aged 18 to 65 who have just been diagnosed with a type of acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome (Ph-negative). The goal is to see how well this therapy works and how safe it is.
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
This Phase 1 study looks at a treatment approach for people newly diagnosed with Philadelphia-negative B- or T-cell acute lymphoblastic leukemia (ALL) after completing a specific chemotherapy course called Hyper-CVAD 1A. It aims to see if the treatment can be given safely and how well it may work for this type of leukemia.
This study follows how well a “pediatric-style” treatment plan works in teens and young adults with Ph-negative acute lymphoblastic leukemia (ALL) in real-world care. It mainly aims to understand outcomes and safety for patients who fit the specific leukemia and health criteria.
This trial tests a new treatment plan for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It aims to see if the combination of drugs can effectively control the leukemia while keeping side effects manageable.
This trial tests a treatment plan for newly diagnosed acute lymphoblastic leukemia (ALL) in people ages 16 to 50. It aims to see how well a “pediatric-style” regimen works, but it only fits certain genetic and health profiles.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.